Home › Funds › Avidity Partners Management LP › PHAT

Avidity Partners Management LP position in PHAT

Phathom Pharmaceuticals, Inc. · Health Care

Avidity Partners Management LP reported holding 200,000 shares of PHAT (Phathom Pharmaceuticals, Inc.) in its Q2 2026 13F filing — a position valued at US$2.2M, representing 0.35% of its reported portfolio and ranking #30 among its reported holdings. Avidity Partners Management LP has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)200.00K sh
Reported value held$2.17M
Portfolio Weight0.35%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Avidity Partners Management LP's PHAT position evolved

Avidity Partners Management LP first disclosed a stake in PHAT in Q3 2023 at 1,617,300 shares (US$16.8M). The position peaked in Q3 2024 at 1,804,493 shares, worth US$32.6M. Across 12 filings, Avidity Partners Management LP increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 200,000 shares valued at US$2.2M — a reduction of -49,390 shares quarter over quarter.. Notable position changes include a 42% trim in Q1 2025 (shares rose 53% over the following quarter), a 33% increase in Q2 2025 (shares rose 23% over the following quarter), a 71% trim in Q3 2025 (shares rose 41% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.62M $16.77M New
Q4 2023 1.72M $15.72M Add
Q1 2024 1.74M $18.43M Add
Q2 2024 1.62M $16.69M Reduce
Q3 2024 1.80M $32.63M Add
Q4 2024 1.39M $11.29M Reduce
Q1 2025 800.00K $5.02M Reduce
Q2 2025 1.06M $10.21M Add
Q3 2025 306.00K $3.60M Reduce
Q4 2025 206.08K $3.42M Reduce
Q1 2026 249.39K $2.77M Add
Q2 2026 200.00K $2.17M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PHAT and 13F data

PHAT (Phathom Pharmaceuticals, Inc.) is a Health Care company. 31 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$81.0M), Carlyle Group Inc. (US$37.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PHAT

All PHAT fund holders →

FAQ

How long has Avidity Partners Management LP held PHAT?

Avidity Partners Management LP has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Avidity Partners Management LP's current position in PHAT?

As of Q2 2026, Avidity Partners Management LP holds 200.00K shares of PHAT (Phathom Pharmaceuticals, Inc.), valued at $2.17M, representing 0.35% of its reported portfolio and ranking #30.

Has Avidity Partners Management LP been buying or selling PHAT?

In the latest 13F filing (Q2 2026), Avidity Partners Management LP reduced its position in PHAT. The position peaked in Q3 2024 at 1.80M shares.

Which other funds hold PHAT?

Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.